Osimertinib: observed
58 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLCRecruitingNCT07837739Report a problem
- Barriers and Facilitators of Persistence With Adjuvant OsimertinibRecruitingNCT07542210Report a problem
- Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC PatientsRecruitingNCT07363252Report a problem
- A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer PatientsNot yet recruitingNCT07338396Report a problem
- Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung CancerRecruitingNCT07028489Report a problem
- UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ AllianceRecruitingNCT06726720Report a problem
- AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain MetastasesRecruitingNCT06604689Report a problem
- ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerRecruitingNCT06532149Report a problem
- A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLCRecruitingNCT06422546Report a problem
- Efficacy of Osimertinib in Patients With Lung CancerRecruitingNCT06174857Report a problem
- OSIREAL - Osimertinib RWE on EGFRm NSCLC in SpainRecruitingNCT06068049Report a problem
- Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)RecruitingNCT05598528Report a problem
- Osimertinib for Advanced EGFR-positive NSCLC PatientsRecruitingNCT05037331Report a problem
- Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLCRecruitingNCT04324164Report a problem
- LAT for Oligoprogressive NSCLC Treated With First-line OSImertinibRecruitingNCT04216121Report a problem
- A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients TreatmentRecruitingNCT01994057Report a problem
- A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.CompletedNCT05834348Results postedReport a problem
- The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by OsimertinibCompletedNCT04179890Results postedReport a problem
- Afatinib Osimertinib Sequencing NISCompletedNCT03370770Results postedReport a problem
- Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung AdenocarcinomaCompletedNCT07857694Report a problem
- Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With OsimertinibCompletedNCT07559526Report a problem
- Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain MetastasesActive, not recruitingNCT07491211Report a problem
- Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung CancerCompletedNCT07267247Report a problem
- Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.CompletedNCT07213076Report a problem
- Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1CompletedNCT07036016Report a problem
- Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records DatabasesCompletedNCT06675695Report a problem
- Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLCCompletedNCT06613633Report a problem
- Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC PatientsActive, not recruitingNCT06538038Report a problem
- The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung CancerCompletedNCT06477055Report a problem
- Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingNCT06376084Report a problem
- A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC RegionCompletedNCT06039683Report a problem
- Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerStatus unknownNCT05513664Report a problem
- Osimertinib for NSCLC With Uncommon EGFR MutationsSuspendedNCT05421936Report a problem
- Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI TherapyStatus unknownNCT05314296Report a problem
- Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung CancerActive, not recruitingNCT05127382Report a problem
- Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR MutationsActive, not recruitingNCT05103605Report a problem
- Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung CancerActive, not recruitingNCT05020275Report a problem
- First Line Osimertinib in the Real World: an Inter-regional Prospective StudyCompletedNCT04965701Report a problem
- Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other TherapyStatus unknownNCT04930133Report a problem
- Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world StudyStatus unknownNCT04575415Report a problem
- Resistance to Oral Therapy in Lung CancerCompletedNCT04546282Report a problem
- Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Retrospective StudyActive, not recruitingNCT04397432Report a problem
- First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese SettingStatus unknownNCT04391283Report a problem
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyStatus unknownNCT04115410Report a problem
- Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLCCompletedNCT04105153Report a problem
- Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUSCompletedNCT03918304Report a problem
- Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positiveCompletedNCT03790397Report a problem
- Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)Status unknownNCT03532698Report a problem
- A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC PatientsCompletedNCT03485326Report a problem
- An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung CancerCompletedNCT03457220Report a problem
- Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.CompletedNCT03219970Report a problem
- Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive PatientsCompletedNCT03137264Report a problem
- Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLCCompletedNCT03133234Report a problem
- Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)TerminatedNCT03053297Report a problem
- PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC PatientsStatus unknownNCT03029858Report a problem
- KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)CompletedNCT02777567Report a problem
- Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)CompletedNCT02756039Report a problem
- AZD9291 US Expanded Access ProgramNo longer availableNCT02451852Report a problem